Halofuginoni on lääkkeellisessä käytössä antiparasiittiaineena . Se on quinazolinoni ja sitä on annettu ihmiselle turvallisesti.Nyt sen ominaisuudet myös antiangiogeenisenä aineena saattaa lisätä sen käyttöalueita.
estämään patologista angiogeneesiä.
Tämä voi olla hyvinkin tärkeä asia ottaen huomioon miten tavallista on angiogeneesista johtuvat silmätaudit Pohjoismaissa.
(Suomennettava myöhemmin)
Lähde:
Elkin M, Miao HQ et al. Halofuginone: a potent inhibitor of critical steps in angiogenesis progression.FASEB J. 2000 Dec;14(15):2477-85. Departments of Oncology, Hadassah-Hebrew University Hospital, Jerusalem, Israel.
Tiivistelmä. Abstract
estämään patologista angiogeneesiä.
Tämä voi olla hyvinkin tärkeä asia ottaen huomioon miten tavallista on angiogeneesista johtuvat silmätaudit Pohjoismaissa.
(Suomennettava myöhemmin)
Lähde:
Elkin M, Miao HQ et al. Halofuginone: a potent inhibitor of critical steps in angiogenesis progression.FASEB J. 2000 Dec;14(15):2477-85. Departments of Oncology, Hadassah-Hebrew University Hospital, Jerusalem, Israel.
Tiivistelmä. Abstract
We
have previously demonstrated that halofuginone, a low molecular weight
quinazolinone alkaloid, is a potent inhibitor of collagen alpha1(I) and
matrix metalloproteinase 2 (MMP-2) gene expression. Halofuginone also
effectively suppresses tumor progression and metastasis in mice. These
results together with the well-documented role of extracellular matrix
(ECM) components and matrix degrading enzymes in formation of new blood
vessels led us to investigate the effect of halofuginone on the
angiogenic process. In a variety of experimental system, representing
sequential events in the angiogenic cascade, halofuginone treatment
resulted in profound inhibitory effect. Among these are the abrogation
of endothelial cell MMP-2 expression and basement membrane invasion,
capillary tube formation, and vascular sprouting, as well as deposition
of subendothelial ECM. The most conclusive anti-angiogenic activity of
halofuginone was demonstrated in vivo (mouse corneal micropocket assay)
by showing a marked inhibition of basic fibroblast growth factor (bFGF)
-induced neovascularization in response to systemic administration of
halofuginone, either i.p. or in the diet. The ability of halofuginone to
interfere with key events in neovascularization, together with its oral
bioavailability and safe use as an anti-parasitic agent, make it a
promising drug for further evaluation in the treatment of a wide range
of diseases associated with pathological angiogenesis.
Inga kommentarer:
Skicka en kommentar